Interval debulking surgery for advanced epithelial ovarian cancer-Reference-Cited by-同舟云学术

Interval debulking surgery for advanced epithelial ovarian cancer

Published:2016-01-09 Issue:1 Volume:2016 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Tangjitgamol Siriwan¹,Manusirivithaya Sumonmal²,Laopaiboon Malinee³,Lumbiganon Pisake⁴,Bryant Andrew⁵

Affiliation:

1. Faculty of Medicine Vajira Hospital, Navamindradhiraj University; Department of Obstetrics and Gynaecology; 681 Samsen Road Dusit District Bangkok Thailand 10300

2. Research Facilitation Divison, Faculty of Medicine Vajira Hospital; Navamindradhirij University Khon Kaen Thailand 40002

3. Khon Kaen University; Department of Biostatistics and Demography, Faculty of Public Health; 123 Mitraparb Road Amphur Muang Khon Kaen Thailand 40002

4. Khon Kaen University; Department of Obstetrics and Gynaecology, Faculty of Medicine; 123 Mitraparb Road Amphur Muang Khon Kaen Thailand 40002

5. Newcastle University; Institute of Health & Society; Medical School New Build Richardson Road Newcastle upon Tyne UK NE2 4AX

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD006014.pub7/fullpdf

Reference68 articles.

1. Intervention debulking surgery in advanced epithelial ovarian cancer;Redman;British Journal of Obstetrics and Gynaecology,1994

2. Varma R Blackledge G Redman C Luesley D Chan KK Mould J A randomised trial of intervention debulking surgery and the duration of cis-platinum combination chemotherapy in advanced epithelial ovarian cancer (EOC) Annals of Oncology 1990 4

3. Rose PG Nerenston S Brady MF Clarke Pearson D Olt G Rubin SC Operative morbidity following primary and interval debulking surgery for advanced ovarian cancer Proceedings of the American Society of Clinical Oncology 2004 450

4. Rose PG Nerenstone S Brady M Clarke Pearson D Olt G Rubin SC A phase III randomised study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study Proceedings of the American Society of Clinical Oncology 2002 201a

5. Secondary surgical cytoreduction for advanced ovarian carcinoma;Rose;The New England Journal of Medicine,2004

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

2. Primary cytoreductive surgery followed by chemotherapy compared to neoadjuvant chemotherapy followed by cytoreduction as a treatment for stage III and IV ovarian cancer (literature review);Tumors of female reproductive system;2024-05-18

3. The Role of Interleukin 6 (IL6), Cancer Antigen—125 (CA-125), and Human Epididymis Protein 4 (HE4) to predict tumor resectability in the advanced epithelial ovarian cancer patients;PLOS ONE;2023-10-04

4. Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients;Cancers;2023-08-03

5. Cytoreductive Surgery with HIPEC as Primary Treatment for Advanced Epithelial Ovarian Carcinoma: Upfront or Interval—ISPSM Collaborative Study;Indian Journal of Surgical Oncology;2023-05-09